- Home
- CTRM vs XCUR Comparison
CTRM vs XCUR Comparison
Compare CTRM & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTRM | XCUR |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 20.3M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CTRM | XCUR |
|---|---|---|
| Price | $2.13 | $2.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 72.2K | 11.9K |
| Earning Date | 04-15-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.66 | $2.62 |
| 52 Week High | $2.65 | $9.75 |
Technical Indicators
Market Signals| Indicator | CTRM | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 42.97 |
| Support Level | $1.95 | $2.63 |
| Resistance Level | $2.18 | $3.50 |
| Average True Range (ATR) | 0.15 | 0.26 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 48.59 | 36.14 |
Price Performance
Historical ComparisonAbout CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
About XCUR Exicure Inc.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.